Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705672 | 0.83 | KMT2A (0.45) | KMT2AHTR2ACYP2D6TSHRMEN1 | |
| SCHEMBL701331 | 0.79 | KMT2A (0.42) | KMT2AHTR2ATSHRMEN1EPHX1 | |
| SCHEMBL27292943 | 0.79 | AOC3 (0.42) | KMT2ATSHREPHX1TAAR1 | |
| SCHEMBL7770298 | 0.77 | CA1 (0.48) | KMT2ACYP2D6TSHRCYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL13724468 | 0.77 | AOC3 (0.41) | KMT2ATSHRALDH1A1TAAR1 | |
| SCHEMBL25437594 | 0.76 | CYP3A4 (0.39) | KMT2AHTR2ACYP3A4CYP2D6TSHR | |
| SCHEMBL5727862 | 0.74 | KMT2A (0.42) | KMT2ACYP3A4CYP2D6TSHRHSD17B10 | |
| SCHEMBL14675504 | 0.74 | KMT2A (0.52) | KMT2ATSHRPKMALDH1A1LMNA | |
| SCHEMBL15514630 | 0.73 | KMT2A (0.50) | KMT2ACYP2D6TSHRPKMMEN1 | |
| SCHEMBL8704293 | 0.73 | KMT2A (0.50) | KMT2ATSHRCYP2C19HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110433162-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-12 | — | — | CN | disclosed |
| CN-110403938-A | It can be used as the dihydronaphthridine and related compound of the kinase inhibitor for treating proliferative disease | DECIPHERA PHARMACEUTICALS LLC | 2019-11-05 | — | — | CN | disclosed |
| CN-104902895-B | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 德西费拉制药有限责任公司 | 2019-03-29 | — | — | CN | disclosed |
| US-20140023668-A1 | C5-C6 OXACYCLIC-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-01-23 | — | — | US | disclosed |
| CN-1131160-A | Process for producing alpha-L-aspartyldipeptide amide derivatives | AJINOMOTO KK (JP) | 1996-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023668-A1 | C5-C6 OXACYCLIC-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, PSEN1 | KMT2A 3749/4885HTR2A 1708/4885CYP3A4 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.